insitro is bringing together remarkable advancements to help address a critical need: discovering and developing new drugs. Over the past decades, developing drugs has become increasingly more difficult and expensive, leaving many patients with significant unmet need. A constellation of technologies now makes it possible to construct, perturb, and observe biological model systems in the laboratory, allowing the generation of biomolecular data at unprecedented breadth and scale. At the same time, the tools of data science and machine learning are now solving problems previously thought to be decades away from solution. insitro aims to combine these technologies to develop a new approach to drug development.

Foresite Capital’s portfolio has an emphasis on companies employing the tools of data science and machine intelligence in healthcare. The insitro leadership and investors have a track record of impactful work at the intersection of machine learning and biology.